Matthew D. Wright, M.D.
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor (Joint Appointment), Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, The Woodlands, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | Georgetown University School of Medicine, Washington, DC, US, MD |
| 2012 | Case Western Reserve University, Cleveland, Ohio, US, Bachelor of Arts in Biology, BA |
| 2012 | Case Western Reserve University, Cleveland, Ohio, US, Bachelor of Arts in Spanish, BA |
Postgraduate Training
| 2019-2022 | Clinical Fellowship, Hematology-Oncology, Cleveland Clinic Foundation, Cleveland, Ohio |
| 2016-2019 | Clinical Residency, Internal Medicine, Case Western Reserve University/University Hospitals, Cleveland, Ohio |
Licenses & Certifications
| 2024 | Georgia Composite Medical Board |
| 2024 | Arizona Board of Medical Examiners |
| 2023 | Tennessee Board of Medical Examiners |
| 2023 | Louisiana State Board of Medical Examiners |
| 2023 | Washington State Department of Health |
| 2023 | Mississippi State Board of Medical Licensure |
| 2023 | Florida Board of Medicine |
| 2023 | Texas Medical Board |
| 2023 | Oklahoma State Board of Medical Licensure |
| 2022 | Alabama Board of Medical Examiners |
| 2022 | BLS |
| 2021 | DEA |
| 2021 | Ohio Medical Board |
| 2019 | American Board of Internal Medicine, Certification in Internal Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Program Director, Medical Oncology Clinical Observer Program, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2025 - Present
Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - 2025
Other Professional Positions
Member, Cleveland Clinic Internal Medicine Residency Hematology-Oncology Interest Group, Cleveland, OH, 2021 - 2022
Member, Cleveland Clinic Hematology-Oncology Program Evaluation Committee, Cleveland, OH, 2020 - 2022
Hufnagel Society M4 Council Representative, Georgetown Learning Societies, Washington, DC, 2015 - 2016
Extramural Institutional Committee Activities
Participant, Project ECHO (Indonesia), The University of Texas MD Anderson Cancer Center, 2026 - Present
Member, HALs The Woodlands Patient Experience Committee, The University of Texas MD Anderson Cancer Center, 2026 - Present
Member, Faculty Senate Travel Subcommittee, The University of Texas MD Anderson Cancer Center, 2025 - 2025
Particpant, Project ECHO (Africa), The University of Texas MD Anderson Cancer Center, 2024 - 2026
Member, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Honors & Awards
| 2025 | Awesome Job Award, UT MD Anderson Cancer Center |
| 2025 | Awesome Job Award, UT MD Anderson Cancer Center |
| 2024 | MDACC Patient Experience Award: Top 10% Provider, UT MD Anderson Cancer Center |
| 2023 | HALs The Woodlands Employee of the Month, UT MD Anderson Cancer Center |
| 2020 | Cleveland Clinic Caregiver Appreciation Award (3) |
| 2014 | McVay Scholarship |
| 2012 | Summa cum laude, Case Western Reserve University |
| 2012 | Phi Beta Kappa, National Academic Honor Society |
| 2012 | Sigma Delta Pi, National Collegiate Hispanic Studies Honor Society |
| 2011 | Mortar Board, National Collegiate Honor Society |
| 2011 | Outstanding Junior Arts & Sciences |
| 2010 | Phi Beta Kappa Prize |
| 2008 - 2012 | President's Scholarship |
| 2008 | President's Award (Co-Valedictorian) |
| 2008 | Leaders of Tomorrow Award |
| 2008 | Bishop Lamb Award |
| 2007 | Senior Class President |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Breast Medical Oncology: Utilizing Medications to Treat Breast Cancer. Invited. ONCORE Youth Summer Program. Houston, Texas, US.
Regional Presentations
- 2021. Assessing the Impact of Preoperative Breast MRI on Time to Treatment for Invasive Lobular Carcinoma. Invited. San Antonio, TX, US.
- 2021. Comparison of Clinical Features and Outcomes for Pleomorphic Invasive Lobular Carcinoma vs. Non-pleomorphic Invasive Lobular Carcinoma. Invited. San Antonio, TX, US.
National Presentations
- 2020. Lecture. Invited. Morbidity and Mortality Conference. Cleveland, OH, US.
- 2019. Immunotherapy Toxicity. Invited. Senior Grand Rounds. Cleveland, OH, US.
- 2018. Outcomes in Bone Predominant (BP) Urothelial Carcinoma (UC). Invited. Genitourinary Cancers Symposium. San Francisco, CA, US.
- 2016. Recurrence of a Rare Malignancy Manifesting as Multiple Cutaneous Lesions. Invited. Washington, DC, US.
International Presentations
- 2025. BRCA & Cancer-Related Genes. Invited. Grand Rounds. Grand Cayman, KY.
Selected Publications
Peer-Reviewed Articles
- Oesterreich S, Nasrazadani A, Zou J, Carleton N, Onger T, Wright MD, Li Y, Demanelis K, Ramaswamy B, Tseng G, Lee AV, Williams N, Kruse M. Clinicopathological Features and Outcomes Comparing Patients with Invasive Ductal and Lobular Breast Cancer. J Natl Cancer Inst 114(11):1511-1522, 2022. e-Pub 2022. PMID: 36239760.
- Varma R, Wright M, Abraham J, Kruse M. Immune Checkpoint Inhibition in Early-stage Triple-negative Breast Cancer. Expert Rev Anticancer Ther 22(11):1225-38, 2022. e-Pub 2022. PMID: 36278877.
- Cocco D, ElSherif A, Wright MD, Dempster MS, Kruse ML, Li H, Valente SA. Invasive Lobular Breast Cancer: Data to Support Surgical Decision Making. Ann Surg Oncol 28(10):5723-5729, 2021. e-Pub 2021. PMID: 34324111.
- Wright MD, Poe MD, DeRenzo A, Haldal S, Escolar ML. Developmental Outcomes of Cord Blood Transplantation for Krabbe Disease: A 15-year study. Neurology 89(13):1365-1372, 2017. e-Pub 2017. PMID: 28855403.
Review Articles
- Wright MD, Abraham MJ. Preclinical Discovery and Development of Abemaciclib used to Treat Breast Cancer. Expert Opin Drug Discov 16(5):485-496, 2021. e-Pub 2021. PMID: 33280445.
Abstracts
- Mouabbi JA, Raghavendra A, Pasyar S, Roland B, Mukhtar R, Moscol G, Wright MD, Bisen AK, Iheme AN, Barcenas CH, Valero V, Nasrazadani A, Lim B, Ramirez DL, Hassan A, Kuerer H, Adesoye T, Paula P, Meric-Bernstam F, Giordano SH, Litton JK, Layman RM. Validation of the CTS5 as a predictor of late distant recurrence (DR) for HR+ HER2-negative Invasive Lobular Carcinoma (ILC). Clin Cancer Res 32(4_Supplement), 2026. e-Pub 2026.
- Wright MD, Yam C, Iwase T, Nelson B, Bassett R, Singareeka A, Whitman G, Karuturi M, Adrada B, Kizub D, Guirguis M, Buzdar A, Moseley T, Nwosu-Iheme A, Kapoor M, Sukumar J, Thomas P, Barcenas CH, Ibrahim N, Moscol G, Nasrazadani A, Ramirez D, Wright MD, Lee J, Woodward WA, Litton JK, Hunt K, Giordano S, Tripathy D, Valero V, Huo L, Rauch GM, Ueno N. Neosaci-io: neoadjuvant sacituzumab govitecan (sg) + pembrolizumab (pb) in patients (pts) with early-stage tnbc experiencing suboptimal response to keynote-522 Available. Clin Cancer Res 32(4_Supplement), 2026. e-Pub 2026.
- Yam C, Radko A, Huo L, Akshara S, Ohanjanyan E, Yudina A, Kushnarev V, Hill H, Abouharb S, Adrada B, Arun B, Barcenas CH, Bisen A, Brewster A, Buzdar A, Gregor M, Damodaran S, Garber H, Guirguis M, Hassan A, Ibrahim N, Karuturi M, Kong E, Layman R, Moscol G, Mouabbi J, Murthy R, Nasrazadani A, Nelson B, Iheme AN, Oke O, Patel M, Pohlmann P, Ramirez D, Saleem S, Sukumar J, Sun J, Thomas P, Walters R, Wei P, Williams M, Wright M, Woodward W, Hunt K, Litton J, Valero V, Tripathy D, Rauch GM, Goldberg M, Korkut A. Circulating Immune Correlates of Pathological Response to Neoadjuvant Pembrolizumab plus Chemotherapy in High-Risk, Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Res 32(4_Supplement), 2026. e-Pub 2026.
- Yam C, Patel M, Sun J, Adrada BE, Raghavendra AS, Litton JK, Mouabbi JA, Iheme AN, Saleem S, Moscol G, Wright MD, Buzdar A, Murthy RK, Korkut A, Valero V, Tripathy D, Moseley TW, Wei P, Huo L, M Rauch AG. Early on-treatment (on-Rx) tumor volume reduction (TVR) to predict response to the KEYNOTE-522 (KN-522) regimen in early stage triple negative breast cancer (TNBC). Journal of Clinical Oncology 43(16_Supplemental):592, 2025. e-Pub 2025.
- Dempster M, Wright M, Cocco D, Elsherif A, Valente SA, Li H, Kruse ML. Comparison of Gene Expression Profiling Results and Clinical Outcomes Among Patients with Pleomorphic ILC and Classic ILC. Cancer Research 82(4_Supplement), 2022. e-Pub 2022.
- Wright MD, Dempster MS, ElSherif A, Cocco D, Valente SA, Li H, Kruse ML. Comparison of Clinical Features and Outcomes for Pleomorphic Invasive Lobular Carcinoma vs. Non-pleomorphic Invasive Lobular Carcinoma. Cancer Research 82(4_Supplement), 2022. e-Pub 2022.
- Wright MD, Dempster MS, ElSherif A, Cocco D, Valente SA, Li H, Kruse ML. Assessing the Impact of Preoperative Breast MRI on Time to Treatment for Invasive Lobular Carcinoma. Cancer Research 82(4_Supplement), 2022. e-Pub 2022.
- Nelson AA, Wright MD, Khaki AR, Diamantopoulos LK, Kyasaram RK, Nezami B, Dawsey S, Patel K, Eitman C, MacLennan G, Grivas P, Mendiratta P, Ponsky LE, Hoimes CJ. Association of Early Bone Metastases and Outcomes of the Bone Predominant Metastatic Urothelial Carcinoma (BPmUC) Phenotype. J Clin Oncol 37, 2019. e-Pub 2019.
- Nelson AA, Opneja A, Nezami BG, Ponsky LE, Wright MD, Mergler P, Kyasaram RK, Eitman C, Patel K, MacLennan G, Cooney MM, Grivas P, Barata PC, Garcia JA, Fu P, Hoimes CJ. Patterns of Metastases, Treatment (tx), and Outcomes in Bone Predominant (BP) Metastatic Urothelial Carcinoma (mUC). J Clin Oncol 36, 2018. e-Pub 2018.
- Yam C, lwase T, Nelson B, Jr RB, Singareeka A, Whitman G, Karuturi M, Adrada B, Kizub D, Guirguis M, Buzdar A, Moseley T, Nwosu-lheme A, Kapoor M, Sukumar J, Thomas P, Barcenas CH, Ibrahim N, Moscol G, Nasrazadani A, Ramirez D, Wright M, Lee J, Woodward WA, Litton JK, Hunt KK, Giordano S, Tripathy D, Valero V, Hua L, Rauch GM, Ueno NT. NeoSaci-10: Neoadjuvant sacituzumab govitecan + pembrolizumab in patients with early-stage TNBC experiencing suboptimal response to KEVNOTE-522. San Antonio Breast Cancer Symposium.
- Yam, Wright MD, Radko A, Huo L, Singareeka A, Ohanjanyan E, Yudina A, Kushnarev V, Hill H, Abouharb S, Adrada B, Arun B, Barcenas C, Bisen A, Brewster A, Buzdar A, Mac Gregor MC, Damodaran S, Garber H, Guirguis M, Hassan A, Ibrahim N, Karuturi M, Kong E, Layman R, Moscol G, Mouabbi J, Murthy R, Nasrazadani A, Nelson B, Iheme AN, Oke O, Patel M, Pohlmann P, Ramirez D, Saleem S, Sukumar J, Sun J, Thomas P, Walters R, Wei P, Williams M, Wright M, Woodward WA, Hunt KK, Litton JK, Valero V, Tripathy D, Rauch G, Goldberg M, Korkut A. Circulating Immune Correlates of Pathological Response to Neoadjuvant Pembrolizumab Plus Chemotherapy in High-Risk, Early-Stage Triple-Negative Breast Cancer. San Antonio Breast Cancer Symposium.
Web Publications
- Wright MD. Benign vs. Malignant Tumors: Their differences, explained, 2026.
- Wright MD. Online Publication for Blood Management for the Cleveland Clinic Foundation, 2021.
- Wright MD, Kruse M. Speaking of Women's Health-What You Should Know About Metastatic Breast Cancer (MBC), 2021.
- Wright MD. Neoplasms 101: What they are and how they’re treated.
Patient Reviews
CV information above last modified September 22, 2026